Canada markets close in 5 hours 1 minute
  • S&P/TSX

    20,799.41
    +58.97 (+0.28%)
     
  • S&P 500

    4,170.42
    -9.34 (-0.22%)
     
  • DOW

    34,082.57
    +28.63 (+0.08%)
     
  • CAD/USD

    0.7481
    -0.0030 (-0.40%)
     
  • CRUDE OIL

    77.38
    +1.50 (+1.98%)
     
  • BTC-CAD

    31,571.70
    -516.30 (-1.61%)
     
  • CMC Crypto 200

    539.78
    +2.92 (+0.54%)
     
  • GOLD FUTURES

    1,888.50
    -42.30 (-2.19%)
     
  • RUSSELL 2000

    2,003.76
    +2.53 (+0.13%)
     
  • 10-Yr Bond

    3.5380
    +0.1420 (+4.18%)
     
  • NASDAQ

    12,173.43
    -27.39 (-0.22%)
     
  • VOLATILITY

    18.43
    -0.30 (-1.60%)
     
  • FTSE

    7,905.08
    +84.92 (+1.09%)
     
  • NIKKEI 225

    27,509.46
    +107.41 (+0.39%)
     
  • CAD/EUR

    0.6891
    +0.0009 (+0.13%)
     

When Should You Buy Cross Country Healthcare, Inc. (NASDAQ:CCRN)?

Cross Country Healthcare, Inc. (NASDAQ:CCRN), is not the largest company out there, but it led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. As a stock with high coverage by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. But what if there is still an opportunity to buy? Let’s take a look at Cross Country Healthcare’s outlook and value based on the most recent financial data to see if the opportunity still exists.

View our latest analysis for Cross Country Healthcare

What's The Opportunity In Cross Country Healthcare?

Great news for investors – Cross Country Healthcare is still trading at a fairly cheap price according to my price multiple model, where I compare the company's price-to-earnings ratio to the industry average. I’ve used the price-to-earnings ratio in this instance because there’s not enough visibility to forecast its cash flows. The stock’s ratio of 5.78x is currently well-below the industry average of 20.64x, meaning that it is trading at a cheaper price relative to its peers. What’s more interesting is that, Cross Country Healthcare’s share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market.

What does the future of Cross Country Healthcare look like?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. However, with an extremely negative double-digit change in profit expected over the next couple of years, near-term growth is certainly not a driver of a buy decision. It seems like high uncertainty is on the cards for Cross Country Healthcare, at least in the near future.

What This Means For You

Are you a shareholder? Although CCRN is currently trading below the industry PE ratio, the adverse prospect of negative growth brings about some degree of risk. I recommend you think about whether you want to increase your portfolio exposure to CCRN, or whether diversifying into another stock may be a better move for your total risk and return.

Are you a potential investor? If you’ve been keeping an eye on CCRN for a while, but hesitant on making the leap, I recommend you dig deeper into the stock. Given its current price multiple, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.

In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. While conducting our analysis, we found that Cross Country Healthcare has 2 warning signs and it would be unwise to ignore these.

If you are no longer interested in Cross Country Healthcare, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here